Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which thyroid test spares more patients from unneeded surgery?

NCT ID NCT02681328

Ongoing Diagnosis Sponsor: Jonsson Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two genetic tests, Afirma GSC and ThyroSeq v.3, on tissue from thyroid nodules that have unclear biopsy results. The goal is to see which test better identifies benign nodules, so patients can avoid unnecessary surgery. About 328 participants with indeterminate thyroid nodules are enrolled. The results could help doctors choose the best test to preserve quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Molecular diagnostic tests (Afirma GSC and ThyroSeq v.3) on thyroid tissue
What this could lead to
If successful, this could help doctors more accurately identify which thyroid nodules are benign, allowing many patients to safely avoid surgery and preserve their quality of life.
What could go wrong
This is a diagnostic comparison study, not a treatment trial. The tests may not perform as hoped, and results may not apply to all patients or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THYROID are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

thyroid gland disorder thyroid tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

THYROID

Contacts and locations

Locations

  • Jonsson Comprehensive Cancer Center at UCLA

    Los Angeles, California, 90095-1781, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.